Dorsey & Whitney Trust CO LLC bought a new position in Agilent Technologies, Inc. (NYSE:A) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,493 shares of the medical research company’s stock, valued at approximately $208,000.
Several other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. lifted its holdings in Agilent Technologies by 1,946.9% during the 1st quarter. BlackRock Inc. now owns 23,119,219 shares of the medical research company’s stock worth $1,222,310,000 after buying an additional 21,989,739 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Agilent Technologies by 45.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock worth $720,358,000 after buying an additional 3,779,099 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in Agilent Technologies during the 1st quarter worth $58,065,000. Marshall Wace North America L.P. acquired a new position in Agilent Technologies during the 1st quarter worth $58,065,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in Agilent Technologies during the 2nd quarter worth $58,693,000.
In other news, CEO Michael R. Mcmullen sold 16,492 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $65.33, for a total transaction of $1,077,422.36. Following the completion of the sale, the chief executive officer now directly owns 211,872 shares of the company’s stock, valued at $13,841,597.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $61.26, for a total transaction of $306,300.00. Following the sale, the insider now directly owns 45,138 shares of the company’s stock, valued at $2,765,153.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 155,165 shares of company stock valued at $9,768,409.
Agilent Technologies, Inc. (NYSE A) opened at 65.96 on Monday. The stock has a 50 day moving average price of $62.40 and a 200-day moving average price of $58.01. Agilent Technologies, Inc. has a 1-year low of $42.92 and a 1-year high of $66.42. The firm has a market cap of $21.23 billion, a P/E ratio of 34.02 and a beta of 1.30.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm posted $0.49 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. Equities research analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current year.
Several research firms have issued reports on A. Jefferies Group LLC upped their price objective on Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Bank of America Corporation reaffirmed an “equal weight” rating on shares of Agilent Technologies in a report on Tuesday, August 15th. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Deutsche Bank AG upped their price objective on Agilent Technologies from $58.00 to $62.00 and gave the stock a “buy” rating in a report on Monday, May 22nd. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a report on Wednesday, August 16th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $63.91.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.